Xbrane Biopharma AB Working Capital to Net Assets Ratio
Xbrane Biopharma AB working capital to net assets ratio. Xbrane Biopharma AB (XBRANE) has a Working Capital to Net Assets ratio of 41.0% as of June 2026. Working capital of Skr220.98 Million (current assets of Skr321.77 Million minus current liabilities of Skr100.79 Million) is measured against net assets of Skr538.85 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Xbrane Biopharma AB tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Xbrane Biopharma AB (2012–2025)
Working capital to net assets ratio of Xbrane Biopharma AB from 2012 to 2025. This chart shows how Xbrane Biopharma AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 41.0%, reflecting working capital of Skr220.98 Million against net assets of Skr538.85 Million SEK. See XBRANE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Xbrane Biopharma AB Working Capital to Net Assets Ratio by Year (2012–2025)
Xbrane Biopharma AB working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Xbrane Biopharma AB balance sheet assets.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.5% | Skr322.47 Million | Skr560.65 Million | Skr375.13 Million | Skr52.66 Million | ▲ +24.9 pp |
| 2024 | 32.6% | Skr67.96 Million | Skr208.54 Million | Skr605.90 Million | Skr537.94 Million | ▼ -46.3 pp |
| 2023 | 78.9% | Skr135.14 Million | Skr171.34 Million | Skr461.69 Million | Skr326.56 Million | ▲ +13.7 pp |
| 2022 | 65.2% | Skr276.95 Million | Skr424.89 Million | Skr513.52 Million | Skr236.57 Million | ▼ -13.9 pp |
| 2021 | 79.1% | Skr341.34 Million | Skr431.74 Million | Skr561.01 Million | Skr219.67 Million | ▲ +7.1 pp |
| 2020 | 72.0% | Skr185.49 Million | Skr257.71 Million | Skr374.48 Million | Skr188.99 Million | ▲ +13.2 pp |
| 2019 | 58.8% | Skr108.32 Million | Skr184.32 Million | Skr247.94 Million | Skr139.62 Million | ▲ +58.4 pp |
| 2018 | 0.3% | Skr277.00K | Skr83.07 Million | Skr161.66 Million | Skr161.38 Million | ▼ -11.2 pp |
| 2017 | 11.5% | Skr10.21 Million | Skr88.41 Million | Skr28.10 Million | Skr17.89 Million | ▼ -23.5 pp |
| 2016 | 35.1% | Skr37.64 Million | Skr107.30 Million | Skr43.53 Million | Skr5.88 Million | ▲ +68.7 pp |
| 2015 | -33.6% | Skr-15.97 Million | Skr47.51 Million | Skr7.43 Million | Skr23.40 Million | ▼ -131.5 pp |
| 2014 | 97.9% | Skr6.17 Million | Skr6.30 Million | Skr6.56 Million | Skr390.70K | ▼ -2.1 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr88.11K | Skr657.01K | Skr568.90K | — |